Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis-Reference-Cited by-同舟云学术

Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis

Published:2009-01 Issue:1 Volume:5 Page:91-102
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Berger William E

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/17425250802670474

Reference39 articles.

1. Bielory L, Ambrosio P. Conjunctivitis and allergic eye diseases. In: Kaliner MA, editor, Current Reviews of Rhinitis. Philadelphia, PA: Current Medicine, Inc; 2002:115-22

2. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis

3. Bernstein JA, Rezvani M. Mixed rhinitis: a new subclass of chronic rhinitis? second edition. In: Kaliner MA, editor, Current Reviews of Rhinitis, Philadelphia, PA: Current Medicine, Inc; 2006:69-78

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacometric Modeling of the Impact of Azelastine Nasal Spray on SARS-CoV-2 Viral Load and Related Symptoms in COVID-19 Patients;Pharmaceutics;2022-09-27

2. Different Methods and Formulations of Drugs and Vaccines for Nasal Administration;Pharmaceutics;2022-05-17

3. The Nose as a Route for Therapy: Part 1. Pharmacotherapy;Frontiers in Allergy;2021-02-22

4. Rhinitis 2020: A practice parameter update;Journal of Allergy and Clinical Immunology;2020-10

5. Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents;Frontiers in Pharmacology;2019-03-29